Barr Strikes Back At Celgene In Thalomid Spat
Barr Laboratories has fired back at Celgene Corp. in a patent suit over the market for Celgene's cancer treatment Thalomid, alleging that Celgene's patents are invalid and accusing Celgene of violating...To view the full article, register now.
Already a subscriber? Click here to view full article